Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct 8:13:e57183.
doi: 10.2196/57183.

Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT)

Luca Bertolaccini #  1 , Oriana Ciani #  2 , Marco Lucchi  3 , Francesco Zaraca  4 , Alessandro Bertani  5 , Roberto Crisci  6 , Lorenzo Spaggiari  1   7 ; LUCENT Study Group  8
Collaborators, Affiliations
Observational Study

Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT)

Luca Bertolaccini et al. JMIR Res Protoc. .

Erratum in

Abstract

Background: Lung cancer, predominantly non-small cell lung cancer (NSCLC), remains a formidable challenge, necessitating an in-depth understanding of evolving treatment paradigms. The Italian Lung Cancer Observational Study (LUCENT) addresses this need by investigating the outcomes of patients with early and locally advanced lung cancer in Italy.

Objective: With a focus on real-world data and patient registries, this study aims to provide comprehensive insights into clinical, psychosocial, and economic impacts, contributing to informed decision-making in health care.

Methods: LUCENT is a prospective observational multicenter cohort study enrolling patients eligible for minimally invasive manual, robot-assisted, or traditional open surgery. The study will develop a web-based registry to collect longitudinal surgical, oncological, and socioeconomic outcome data. The primary objectives include performance assessment through the establishment of national benchmarks based on risk-adjusted outcomes and processes of care indicators. The secondary objectives encompass economic and psychosocial impact assessments of innovative technologies and treatment pathways. The multicenter design ensures a diverse and representative study population.

Results: The evolving landscape of NSCLC treatment necessitates a nuanced approach with consideration of the dynamic shifts in therapeutic strategies. LUCENT strives to fill existing knowledge gaps by providing a platform for collecting and analyzing real-world data, emphasizing the importance of patient-reported outcomes in enhancing the understanding of the disease. By developing a web-based registry, the study not only facilitates efficient data collection but also addresses the limitations of traditional methods, such as suboptimal response rates and costs associated with paper-and-pencil questionnaires. Recruitment will be conducted from January 01, 2024, to December 31, 2026. Follow-up will be performed for a minimum of 2 years. The study will be completed in the year 2028.

Conclusions: LUCENT's potential implications are substantial. Establishing national benchmarks will enable a thorough evaluation of outcomes and care processes, guiding clinicians and policymakers in optimizing patient management. Furthermore, the study's secondary objectives, focusing on economic and psychosocial impacts, align with the contemporary emphasis on holistic cancer care. Insights gained from this study may influence treatment strategies, resource utilization, and patient well-being, thereby contributing to the ongoing refinement of lung cancer management.

Trial registration: ClinicalTrials.gov NCT05851755; https://clinicaltrials.gov/study/NCT05851755. ISRCTN 67197140; https://www.isrctn.com/ISRCTN67197140.

International registered report identifier (irrid): PRR1-10.2196/57183.

Keywords: economic aspects; lung cancer; multicenter study; observational study; quality of life.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Bertolaccini L, Casiraghi M, Bardoni C, Diotti C, Chiari M, Mazzella A, de Marinis F, Spaggiari L. Revamping non-small cell lung cancer treatments in stages II and III: Preparing healthcare for cutting-edge immuno-oncology regimens. Cancers (Basel) 2024 Aug 14;16(16):2842. doi: 10.3390/cancers16162842. https://www.mdpi.com/resolver?pii=cancers16162842 cancers16162842 - DOI - PMC - PubMed
    1. Shahian DM, Fernandez FG, Badhwar V. The Society of Thoracic Surgeons National Database at 30: Honoring our heritage, celebrating the present, evolving for the future. Ann Thorac Surg. 2019 Apr;107(4):1259–1266. doi: 10.1016/j.athoracsur.2019.02.002.S0003-4975(19)30232-2 - DOI - PubMed
    1. Jacobs JP, Shahian DM, D'Agostino RS, Mayer JE, Kozower BD, Badhwar V, Thourani VH, Jacobs ML, Gaissert HA, Fernandez FG, Naunheim KS. The Society of Thoracic Surgeons National Database 2018 annual report. Ann Thorac Surg. 2018 Dec;106(6):1603–1611. doi: 10.1016/j.athoracsur.2018.10.001.S0003-4975(18)31477-2 - DOI - PubMed
    1. Farjah F, Kaji AH, Chu D. Practical guide to surgical data sets: Society of Thoracic Surgeons (STS) National Database. JAMA Surg. 2018 Oct 01;153(10):955–956. doi: 10.1001/jamasurg.2018.0545.2677727 - DOI - PubMed
    1. Shapira OM, Blumenfeld O, Bolotin G, Grover FL, Shahian DM. International participation in The Society of Thoracic Surgeons Adult Cardiac Surgery Database: From institutional to national. Ann Thorac Surg. 2017 Jun;103(6):1683–1686. doi: 10.1016/j.athoracsur.2017.01.010.S0003-4975(17)30046-2 - DOI - PubMed

Publication types

Associated data